Pharma Mar
BME:PHM Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 28 Fair Values set on narratives written by author
WA
Consensus Narrative from 6 Analysts
ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
Key Takeaways Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results. PharmaMar's strong cash position and robust pipeline support reinvestment and potential long-term revenue growth, with a stable cost structure enhancing margins.
View narrative€87.17
FV
10.3% overvalued intrinsic discount36.05%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
New narrative